Status:
COMPLETED
Study Evaluating AGG-523 in Subjects With Osteoarthritis
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Osteoarthritis
Eligibility:
All Genders
40+ years
Phase:
PHASE1
Brief Summary
This study will evaluate the effect of AGG-523 administration on biomarkers related to osteoarthritis. Safety and tolerability of AGG-523 will also be assessed.
Eligibility Criteria
Inclusion
- Inclusion:
- Mild to moderate Osteoarthritis of the target knee.
- Subjects must be generally healthy but enrolled with stable chronic illness if well controlled.
Exclusion
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
End Date :
June 1 2007
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00427687
Start Date
February 1 2007
End Date
June 1 2007
Last Update
August 5 2008
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Anaheim, California, United States, 92801
2
Miami, Florida, United States, 33143
3
Altoona, Pennsylvania, United States, 16635